

Filed On Behalf Of:

Novartis Pharmaceuticals Corporation

By:

Nicholas N. Kallas
NKallas@fchs.com
ZortressAfinitorIPR@fchs.com
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED,
Petitioner,

v.

NOVARTIS PHARMACEUTICALS CORPORATION,
Patent Owner.

Case IPR2018-00507
Patent 8,410,131

**PATENT OWNER'S MANDATORY NOTICES
UNDER 37 C.F.R. § 42.8(a)(2)**

REAL PARTY-IN-INTEREST PURSUANT TO 37 C.F.R. § 42.8(b)(1)

Pursuant to the requirements of 37 C.F.R. § 42.8(a)(2), the undersigned states that Novartis Pharmaceuticals Corporation (“Novartis” or “Patent Owner”) owns U.S. Patent No. 8,410,131 (“the ’131 Patent”), and is a wholly-owned subsidiary of Novartis AG. Novartis is the real party-in-interest in IPR2018-00507.

RELATED MATTERS PURSUANT TO 37 C.F.R. § 42.8(b)(2)

The ’131 Patent has been or is at issue in the following judicial proceedings: (1) Novartis Pharm. Corp. et al. v. West-Ward Pharm. Int’l Ltd., No. 15-474-RGA (D. Del.) (final judgement that claims 1-3 of the ’131 Patent were not proven invalid by reason of obviousness entered on December 21, 2017); (2) Novartis Pharm. Corp. et al. v. Breckenridge Pharm., Inc., No. 16-431-RGA (D. Del.); (3) Novartis Pharm. Corp. et al. v. Breckenridge Pharm., Inc., No. 17-420-RGA (D. Del.); (4) Novartis Pharm. Corp. et al. v. Teva Pharm. USA, Inc., No. 17-393-RGA (D. Del.); and (5) Novartis Pharm. Corp. et al. v. West-Ward Pharm. Int’l Ltd., No. 18-1434 (Fed. Cir.) (appeal from No. 15-474-RGA (D. Del.) by West-Ward Pharm. Int’l Ltd.).

The ’131 Patent is also the subject of the following Petition for *Inter Partes* Review: Breckenridge Pharmaceutical, Inc. v. Novartis Pharmaceuticals

Corporation, *Inter Partes* Review No. 2017-01592 (P.T.A.B.) (institution granted January 3, 2018).

**IDENTIFICATION OF LEAD AND BACK-UP COUNSEL
PURSUANT TO 37 C.F.R. §§ 42.8(b)(3) and 42.10**

Pursuant to 37 C.F.R. §§ 42.8(b)(3) and 42.10, Novartis designates Nicholas N. Kallas (Reg. No. 31,530) as lead counsel and Laura K. Fishwick (Reg. No. 69,907) as back-up counsel.

A power of attorney from Novartis is being submitted with this Notice.

SERVICE INFORMATION PURSUANT TO 37 C.F.R. § 42.8(b)(4)

Novartis may be served electronically using the following e-mail address:

ZortressAfinitorIPR@fchs.com

Novartis may be served by postal mailing, hand-delivery, telephone or facsimile as follows:

Nicholas N. Kallas
Fitzpatrick, Cella, Harper & Scinto
1290 Avenue of the Americas
New York, NY 10104
Telephone: (212) 218-2100
Facsimile: (212) 218-2200

Respectfully submitted,

Dated: February 7, 2018

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530

Lead Counsel for Patent Owner
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100

CERTIFICATE OF SERVICE

I certify that a copy of Patent Owner's Mandatory Notices Under 37 C.F.R. § 42.8(a)(2) was served on February 7, 2018 by causing it to be sent by email to counsel for Petitioner at the following email addresses:

Keith A. Zullo (kzullo@goodwinprocter.com)

Marta E. Delsignore (mdelsignore@goodwinprocter.com)

Dated: February 7, 2018

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100